New Horizon Health Limited provided group earnings guidance for the year ended December 31, 2023. For the period, the company expects the total revenue to be within the range of RMB 1,978.8 million to RMB 2,049.8 million, representing an increase in the range of 158.9% to 168.2% from approximately RMB764.4 million for the year ended December 31, 2022. The increase in total revenue was mainly due to the increased revenue and gross profit of the Group's products, namely, ColoClear, UU Tube and Pupu Tube.

In particular, Revenue from sales of ColoClear for the year ended December 31, 2023 is expected to be within the range of RMB 1,176.9 million to RMB 1,209.9 million, representing an increase in the range of 230.6% to 239.9% from approximately RMB 356.0 million for the year ended December 31, 2022. The gross profit from sales of ColoClear for the year ended December 31, 2023 is expected to be within the range of RMB 1,080.6 million to RMB 1,109.6 million, representing an increase in the range of 263.8% to 273.6% from approximately RMB 297.0 million for the year ended December 31, 2022. The increase in the revenue and gross profit from sales of ColoClear is due to (a) the increase in volume of ColoClear sold and recognized as revenue; and (b) the increase in revenue per test due to the average price per unit increased across all sales channels.

Specifically, for the year ended December 31, 2023, hospital channel was the largest revenue contributor and the fastest growing channel for ColoClear, followed by consumer healthcare channel1 and health checkup centers; Revenue from sales of UU Tube for the year ended December 31, 2023 is expected to be within the range of RMB 453.7 million to RMB 472.7 million, representing an increase in the range of 118.3% to 127.5% from approximately RMB 207.8 million for the year ended December 31, 2022. The gross profit from sales of UU Tube for the year ended December 31, 2023 is expected to be within the range of RMB 427.8 million to RMB 446.1 million, representing an increase in the range of 127.1% to 136.8% from approximately RMB 188.4 million for the year ended December 31, 2022. The increase in the revenue and gross profit from sales of UU Tube is due to (a) the increase in volume of UU Tube sold and recognized as revenue; and (b) higher revenue per product in consumer healthcare channel and health checkup centers; and Revenue from sales of Pupu Tube for the year ended December 31, 2023 is expected to be within the range of RMB 346.9 million to RMB 365.9 million, representing an increase in the range of 72.9% to 82.4% from approximately RMB 200.6 million for the year ended December 31, 2022.

The gross profit from sales of Pupu Tube for the year ended December 31, 2023 is expected to be within the range of RMB 305.0 million to RMB 323.3 million, representing an increase in the range of 85.3% to 96.4% from approximately RMB164.6 million for the year ended December 31, 2022. The increase in the revenue and gross profit from sales of Pupu Tube is due to (a) the increase in volume of Pupu Tube sold and recognized as revenue; and (b) higher revenue per product in consumer healthcare channel and health checkup centers.